Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

By P. Tebas, David Stein, Winson W. Tang, I. Frank, Shelley Wang, Gary K. Lee, S. Spratt, R. Surosky, Martin A. Giedlin, G. Nichol and 10 more. New England Journal of Medicine, 2014

1,348 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Virology

View Paper: https://www.semanticscholar.org/paper/b6e404dab5cc3639d4dc82173f59daebad7fa431

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michel Sadelain
2. C. June
3. Feng Zhang
4. P. Hsu
5. J. Keith Joung
6. B. Levine
7. Eric S. Lander
8. K. High

In Molecular Biology

1. Feng Zhang
2. Eric S. Lander
3. P. Hsu
4. J. Keith Joung
5. Howard Y. Chang
6. Min Wu
7. Ansuman T. Satpathy
8. Bijoya Paul

Citations in the corpus

• CRISPR-Cas12a: Functional overview and applications (2020, background): “[7] Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al.”
• CRISPR-engineered T cells in patients with refractory cancer (2020, background): “The first pilot human trials using genome editing were conducted in patients with HIV/AIDS and targeted the white blood cell protein CCR5, with the goal of mutating the CCR5 gene by nonhomologous recombination and thereby inducing resistance to HIV infection (3, 4).”
• Development and Applications of CRISPR-Cas9 for Genome Engineering (2014, positive): “Perturbation of multiple genes simultaneously could model the additive effects that underlie complex polygenic disorders, leading to new drug targets, while genome editing could directly correct harmful mutations in the context of human gene therapy (Tebas et al., 2014).”
• Gene therapy comes of age (2018, positive): “A cohort of phase III–eligible subjects from one of the phase I/II trials continues to demonstrate clinical benefits lasting aminimumof 3 years after injection, with observation ongoing (95); however, patients in the other two original trials have experienced regressionof visual functionover similar”
• mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, background): “Encouragingly, very strong efforts have been made to explore nonviral and in vivo mRNA delivery for efficient and safe gene editing, which is worth looking forwards to in the future.(485)”